Nuclear Medicine and Molecular Imaging

, Volume 53, Issue 4, pp 247–252 | Cite as

Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with 18F-NaF PET/CT

  • Erik M. Velez
  • Bhushan Desai
  • Hossein JadvarEmail author
Original Article



To determine the utility of 18F-sodium fluoride positron emission tomography-computed tomography (18F-NaF PET/CT) in the imaging assessment of therapy response in men with osseous-only metastatic prostate cancer.


In this Institutional Review Board–approved single institution retrospective investigation, we evaluated 21 18F-NaF PET/CT scans performed in 14 patients with osseous metastatic disease from prostate cancer and no evidence of locally recurrent or soft-tissue metastatic disease who received chemohormonal therapy. Imaging-based qualitative and semi-quantitative parameters were defined and compared with changes in serum PSA level.


Qualitative and semi-quantitative image-based assessments demonstrated > 80% concordance with good correlation (SUVmax κ = 0.71, SUVavg κ = 0.62, SUVsum κ = 0.62). Moderate correlation (κ = 0.43) was found between SUVmax and PSA-based treatment response assessments. There was no statistically significant correlation between PSA-based disease progression and semi-quantitative parameters. Qualitative imaging assessment was moderately correlated (κ = 0.52) with PSA in distinguishing responders and non-responders.


18F-NaF PET/CT is complementary to biochemical monitoring in patients with bone-only metastases from prostate cancer which can be helpful in subsequent treatment management decisions.


18F-NaF PET/CT Prostate Cancer Metastasis Bone 



computed tomography


positron emission tomography


prostate-specific antigen


methylene diphosphonate


sodium fluoride










Funding Information

We acknowledge National Institutes of Health grants R01-CA111613 (PI: H. Jadvar) and P30-CA014089 (USC Norris Comprehensive Cancer Center).

Compliance with Ethical Standards

Conflict of Interest

Erik M. Velez, Bhushan Desai, and Hossein Jadvar declare no conflicts of interest. There was no direct funding for this study.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.CrossRefGoogle Scholar
  2. 2.
    O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015;7:202–11.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Jadvar H, Desai B, Conti PS. Sodium 18F-fluoride PET/CT of bone, joint and other disorders. Semin Nucl Med. 2015;45:58–65.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Langsteger W, Rezaee A, Pirich C, Beheshti M. 18F-NaF-PET/CT and 99mTc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med. 2016;46:491–501.CrossRefPubMedGoogle Scholar
  5. 5.
    Iagaru AH, Mittra E, Colletti PM, Jadvar H. Bone-targeted imaging and radionuclide therapy in prostate cancer. J Nucl Med. 2016;57(Suppl 3):19S–24S.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med. 2010;51:1826–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bridges RL, Wiley CR, Christian JC, Strohm AP. An introduction to Na(18)F bone scintigraphy:basic principles, advanced imaging concepts, and case examples. J Nucl Med Technol. 2007;35:64–76.CrossRefPubMedGoogle Scholar
  8. 8.
    Kulshrestha RK, Vinjamuri S, England A, Nightingale J, Hogg P. The role of 18F-sodium fluoride PET/CT bone scans in the diagnosis of metastatic bone disease from breast and prostate Cancer. J Nucl Med Technol. 2016;44:217–22.CrossRefGoogle Scholar
  9. 9.
    Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356–67.PubMedGoogle Scholar
  10. 10.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.Google Scholar
  11. 11.
    Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W. Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-fluorocholine PET/CT. J Nucl Med. 2016;57(Suppl 3):55S–60S.CrossRefPubMedGoogle Scholar
  12. 12.
    Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol. 2012;199:278–91.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Clamp A, danson S, Nguyen H, Cole D, Clemons M. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004;5:607–16.CrossRefPubMedGoogle Scholar
  14. 14.
    Woolf DK, Padhani AR, Makris A. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Ann Oncol. 2015;26:1048–57.CrossRefPubMedGoogle Scholar
  15. 15.
    Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–5.CrossRefGoogle Scholar
  16. 16.
    Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.CrossRefGoogle Scholar
  17. 17.
    Segall G, Delbeke D, Stabin MG, Even-Sapir E, Fair J, Sajdak R, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Ceci F, Castellucci P, Nanni C, Fanti S. PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2103–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Simoncic U, Perlman S, Liu G, Staab MJ, Sraus JE, Jeraj R. Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer. 2015;13:e7–e17.CrossRefPubMedGoogle Scholar
  20. 20.
    Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, et al. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013;54:1195–201.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22:963–9.CrossRefPubMedGoogle Scholar
  22. 22.
    De Giorgi U, Caroli P, Burgio SL, Menna C, Coteduca V, Bianchi E, et al. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014;5:12448–58.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, et al. 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42:1276–83.CrossRefPubMedGoogle Scholar
  24. 24.
    Seitz AK, Rauscher I, Hallr B, Kronke M, Luther S, Heck MM, et al. Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate Cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602–12.CrossRefGoogle Scholar
  25. 25.
    Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Grshen SG, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37:637–43.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Shen CT, Qiu ZL, Han TT, Luo QY. Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis. Clin Nucl Med. 2015;40:103–10.CrossRefGoogle Scholar
  27. 27.
    Jadvar H, Colletti PM. 18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. Br J Radiol. 2018;91(1091):20170948.Google Scholar
  28. 28.
    Cook G Jr, Parker C, Chua S, Johnson B, Aksnes AK, Lweington VJ. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1:4.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, et al. Quantitative assessment of early [18F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol. 2017;35:2829–37.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Muzi M, O’Sullivan F, Muzi J, Mankofff D, Yu E. Whole body 18F-fluoride PET SUV imaging to monitor response to dasatinib therapy in castration-resistant prostate cancer bone metastases: secondary results from ACRIN 6687. J Nucl Med. 2018;59(suppl. 1):1465.Google Scholar
  31. 31.
    Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, et al. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015;56:354–60.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hillner BE, Siegel BA, Hanna L, Duan F, Quinn B, Shields AF. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. J Nucl Med. 2015;56:222–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Gareen IF, Hillner BE, Hann L, Makineni R, Duan F, Shields AF, et al. Hospice admission and survival after 18F-fluoride PET performed for evaluation of osseous metastatic disease in the National Oncologic PET Registry. J Nucl Med. 2018;59:427–33.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Wade AA, Scott JA, Kuter I, Fischman AJ. Flare response in 18F-fluoride ion PET bone scanning. AJR Am J Roentgenol. 2006;186:1783–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, et al. Gleason grade progression is uncommon. Cancer Res. 2013;73:5163–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Division of Nuclear Medicine, Department of Radiology, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations